Description

Actovegin (gemoderivat of blood of calves) Coated Tablets 200 mg. №50 Vial

Ingredients

Each coated tablet contains 200 mg of Actovegin (gemoderivat of blood of calves).

Dosage

The usual dosage is 1-2 tablets three times a day. It is recommended to consult a healthcare professional for personalized dosing instructions.

Indications

Actovegin tablets are indicated for conditions requiring increased energy and metabolism. It is commonly used in the treatment of peripheral arterial disease, diabetic polyneuropathy, and wound healing.

Contraindications

Do not use Actovegin if you are allergic to any of the ingredients. Pregnant and breastfeeding women should consult a doctor before use.

Directions

Take the tablets orally with water, preferably before meals. Follow the instructions provided by your healthcare provider.

Scientific Evidence

Actovegin, a biological drug derived from calf blood, has shown promising results in various clinical studies. Research published in the Journal of Vascular Research demonstrated the efficacy of Actovegin in improving microcirculation and tissue oxygenation, leading to enhanced wound healing and tissue repair. Another study in the Journal of Diabetes Research highlighted the benefits of Actovegin in reducing neuropathic pain and improving nerve function in diabetic patients.

Additional Information

Actovegin is well-tolerated with minimal side effects reported. It is considered a safe and effective treatment option for conditions related to impaired energy metabolism and tissue damage. Consult your healthcare provider for more information on the use of Actovegin.

Pharmacological Effects: Actovegin enhances cellular energy metabolism, improves oxygen utilization, and promotes tissue regeneration. It acts by increasing glucose and oxygen uptake at the cellular level, leading to improved energy production and tissue repair.

Clinical Trials: Several clinical trials have demonstrated the efficacy of Actovegin in various medical conditions, including diabetic neuropathy, peripheral vascular disease, and sports injuries. A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism showed significant improvements in nerve conduction velocity and sensory symptoms in diabetic patients treated with Actovegin compared to placebo.